Added to YB: 2025-12-18
Pitch date: 2025-12-16
NANO.PA [bullish]
Nanobiotix S.A.
-2.08%
current return
Author Info
Lux Opes Research covers European companies. Lots of them. Sign up for the newsletter.
Company Info
Nanobiotix S.A. operates as a clinical-stage biotechnology that focuses on developing product candidates for the treatment of cancer and other unmet medical needs.
Market Cap
EUR 932.5M
Pitch Price
EUR 19.24
Price Target
N/A
Dividend
N/A
EV/EBITDA
-22.31
P/E
-17.76
EV/Sales
94.00
Sector
Biotechnology
Category
growth
Nanobiotix (NANO France): new clinical data strengthen the case for a breakthrough oncology platform
NANO.PA (update): Radiotherapy-activated nanoparticle JNJ-1900 shows dual local tumor control + systemic immune response across melanoma, pancreatic, head/neck cancers. Phase III NANORAY-312 interim data 2027. $45B addressable market by 2030. Janssen partnership + $71M HCRx deal funds to 2028.
Read full article (2 min)